Urology Times· @UrologyTimes · X·· 2 days agoScore70
Body · original
KEYNOTE-866 at #ESMO2026: Adding perioperative pembrolizumab to neoadjuvant cisplatin plus gemcitabine did not significantly improve event-free survival in patients with cisplatin-eligible MIBC. https://www.urologytimes.com/view/adding-perioperative-pembrolizumab-chemotherapy-does-not-improve-efs-mibc
263 views · 1 like · 0 reposts · 0 replies
Conference abstracts
4735Omatched by Proffered paper 1: Genitourinary tumour, renal and urothelial
Perioperative pembrolizumab (pembro) or placebo (pbo) + neoadjuvant cisplatin (cis) and gemcitabine (gem) in participants (pts) with muscle-invasive bladder cancer (MIBC): the double-blind, phase 3 KEYNOTE-866 study
https://esmocongress.esmo.orgSource: Urology Times · x.com